In mixed hematopoietic chimerism, the donor red cells win

Allogeneic hematopoietic stem cell transplantation (HSCT) was first observed to correct the thalassemias and hemoglobinopathies over three decades ago.[1][1],[2][2] Since then, over 3000 transplants for these disorders have been performed worldwide, and allogeneic HSCT currently remains the only

[1]  P. Tazzari,et al.  Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease , 2010, Haematologica.

[2]  J. Stockman.  Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell Disease , 2011 .

[3]  Jérôme Larghero,et al.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.

[4]  A. Mastronuzzi,et al.  Donor/recipient mixed chimerism does not predict graft failure in children with β-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling , 2008, Haematologica.

[5]  D. Neuberg,et al.  Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. , 2008, Experimental hematology.

[6]  G. Federici,et al.  Relationship between mixed chimerism and rejection after bone marrow transplantation in thalassaemia. , 2008, Blood transfusion = Trasfusione del sangue.

[7]  J. Kutok,et al.  Evidence for ineffective erythropoiesis in severe sickle cell disease. , 2005, Blood.

[8]  A. Gow,et al.  Loss of α-hemoglobin–stabilizing protein impairs erythropoiesis and exacerbates β-thalassemia , 2004 .

[9]  A. Gow,et al.  Loss of alpha-hemoglobin-stabilizing protein impairs erythropoiesis and exacerbates beta-thalassemia. , 2004, The Journal of clinical investigation.

[10]  K. Sullivan,et al.  Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  A. Nienhuis,et al.  Functional requirements for phenotypic correction of murine beta-thalassemia: implications for human gene therapy. , 2001, Blood.

[12]  S. Schrier,et al.  A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in thai patients with thalassemia. , 2000, Blood.

[13]  M. Andreani,et al.  Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation , 2000, Bone Marrow Transplantation.

[14]  M. Trudel,et al.  Altered hematopoiesis in murine sickle cell disease. , 1999, Blood.

[15]  N. Young,et al.  Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. , 1999, Blood.

[16]  A. Schechter,et al.  Sickling of nucleated erythroid precursors from patients with sickle cell anemia. , 1998, Experimental hematology.

[17]  MARROW TRANSPLANTATION FOR THALASSAEMIA , 1987, The Lancet.

[18]  A. Look,et al.  Bone-marrow transplantation in a patient with sickle-cell anemia. , 1984, The New England journal of medicine.

[19]  A. Sullivan,et al.  Ultrastructural Studies of the Bone Marrow in Sickle Cell Anaemia , 1975, British journal of haematology.

[20]  A. Sullivan,et al.  Ultrastructural Studies of the Bone Marrow in Sickle Cell Anaemia , 1975, British journal of haematology.